Lack of protective effect of D-003, a mixture of high-molecular-weight primary acids from sugar cane wax, on liver damage induced by galactosamine in rats

Journal of Medicinal Food

Volumn 8, Issue 3, 2005, Pages 343-347

  Noa, Miriam ^a   Mendoza, Sarahi ^a   Mas, Rosa ^a   Mendoza, Nilda ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Acute hepatotoxicity; D 003; Galactosamine; Hepatoprotective effects; Lipid peroxidation

Indexed keywords

CARBON TETRACHLORIDE; CHOLESTEROL; D 003; GALACTOSAMINE; OCTACOSANOIC ACID; PARACETAMOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; LIVER CELL; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; RNA SYNTHESIS; SUGARCANE;

ANIMALS; FATTY ACIDS; GALACTOSAMINE; HEPATOCYTES; INCLUSION BODIES; LIPIDS; LIVER DISEASES; MALE; NECROSIS; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; SACCHARUM; SACCHARUM HYBRID CULTIVAR;

EID: 27144437840     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2005.8.343     Document Type: Article

References (44)

1. Anderson KM, Wilson PWF, Odell PM, et al.: An updated coronary risk profile: A statement for health professionals. Circulation 1991;83:356-362.
2. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in the incidence of coronary heart disease. JAMA 1984;251:351-364.
3. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in the incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374.
4. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
5. Tonkin A, Aylward P, Colqhoun D, et al.: Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339;1349-1357
6. Shepherd S, Cobbe SM, Ford I, et al.: West of Scotland Coronary Prevention: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
7. Downs JR, Clearfield M, Weiss S, et al.: AFCAPS/TexCAPS Rsearch Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-1622.
8. Bhatnagar D: Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol Ther 1998;79:205-230.
9. Farnier M, Davignon J: Current and future treatment of hyperlipidemia: The role of statins. Am J Cardiol 1998;82:3J-10J.
10. Farmer JA, Gotto AM: Choosing the right lipid-regulating agent: A guide to selection. Drugs 1996;52:649-661.
11. Antilipemic agents. In: American Formulary Hospital Service (AFHS) Drug Information. American Society of Health-System Pharmacists, Inc., Bethesda, MD. 2000. pp. 1620-1657.
12. Plaa G, Charbonneau M: Detection and evaluation of chemically induced liver injury. In: Principles and Methods of Toxicology, 3rd ed. (Hayes AW. ed.). Raven Press. New York. 1994. pp. 839-870.
13. Wendal A. Fevertein S: Drug induced lipid peroxidation in mice. I. Modulation by monoxygenase activity, glutathione and selenium stains. Biochem Pharmacol 1981;30:2513-2520.
14. Recknagel RO, Glende EA, Waller RL, Lowry K: Lipid peroxidation: Biochemistry, measurement, and significance in liver cell injury. In: Toxicology of the Liver (Plaa G, Hewitt WR, eds.), Raven Press. New York. 1982. pp. 213-241.
15. Wendel A: Measurement of in vivo lipid peroxidation and toxicological significance. Free Radic Biol Med 1987;3:355-358.
16. Charbonneau M, Iijima M, Coté MG, Plaá GL: Temporal analysis of rat liver injury following potentiation of carbon tetrachloride hepatotoxicity with ketonic or ketogenic compounds. Toxicology 1985;32:95-112.
17. 4 intoxication. J Appl Toxicol 1984;4:270-272.
18. 4 liver damage. J Appl Toxicol 1990; 10:275-279.
19. Noa M, Mendoza S, Mendoza N: Effect of policosanol on carbon tetrachloride-induced acute liver damage in Sprague Dawley rats. Drugs R&D 2003;4:29-35.
20. Mitchell JR, Jollow DJ, Potter WZ, Davis D, Guillete J, Brodie B: Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 1973;187:185-194.
21. Fairhurst S, Barber DJ, Clark B, Horton A: Studies on paracetamol-induced lipid peroxidation. Toxicology 1982;23:249-259.
22. Vermeulen NP, Bessems JG, Van der Straat R: Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention. Drug Metab Rev 1992;24:367-407.
23. Harman AW: The effectiveness of antioxidants in reducing paracetamol-induced damage subsequent to paracetamol activation. Res Commun Chem Pathol Pharmacol 1985;49:215-228.
24. McLean AE, Nuttall L: An in vitro model of liver injury using paracetamol treatment of liver slices and prevention of injury by some antioxidants. Biochem Pharmacol 1978;27:425-430.
25. Ferencikova R, Cervinkova Z, Drahota Z: Hepatotoxic effect of D-galactosamine and protective role of lipid emulsion. Physiol Res 2003;52:73-78.
26. Yoshikawa T, Furukawa Y, Murakami M, Takemura S, Kondo M: Effects of vitamin E on the galactosamine induced or carbon tetrachloride induced hepatotoxicity. Digestion 1982;25:222-229.
27. Castro JA: Prevention on chemically induced liver injury. In: Toxic Interactions (Goldstein R. ed.). Academic Press, New York, 1990, pp. 233-257.
28. González L, Marrero D, Laguna A, et al. inventors; Laboratories Dalmer SA. assignee: Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. Republic of South Africa patent 98-2744. December 30, 1998.
29. Gámez R, Mendoza S, Más R, et al: Dose-dependent cholesterol lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res 2000;61:8-16.
30. Mendoza S. Gámez R, Noa M, Más R, Castaño G: The effects of D-003 and policosanol on the lipid profile and endothelial cells in normocholesterolemic rabbits: A head to head comparison. Curr Ther Res 2001;62:209-220.
31. Menéndez R, Mas R, Amor AM, et al.: Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol Res 2001;44:299-304.
32. Molina V, Arruzazabala ML, Carbajal D, Más R, Valdés S: Antiplatelet and antithrombotic effects of D003. Pharmacol Res 2000;42:137-143.
33. Molina V, Arruzazabala ML, Carbajal D, Más R: D-003, a potential antithrombotic compound isolated from sugar cane wax with effects on arachidonic acid metabolites. Prostaglandins Leukot Essent Fatty Acids 2002;67:19-24.
34. Menéndez R, Mas R, Pérez Y, et al.: Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can J Physiol Pharmacol 2002;80:13-21.
35. Castaño G, Más R, Fernandez L, et al.: Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound in healthy volunteers: A phase I clinical study. Drugs R&D 2002;3:337-348.
36. Arruzazabala ML, Carbajal D, Más R, Molina V, Castaño G: Effects of D-003, a new compound purified from sugar cane wax, on platelet aggregation in healthy volunteers. A randomised double-blind clinical study. Clin Drug Invest 2003; 23:107-118.
37. Arruzazabala ML, Mas R, Molina V, et al.: Effects of D-003, a new substance purified from sugar cane wax, on platelet aggregation and plasma levels of arachidonic acid metabolites in healthy volunteers. Int J Clin Pharmacol Res 2004;24:55-63.
38. Castaño G, Menéndez R, Más R, et al.: Effects of D-003: A new hypocholesterolaemic and antiplatelet compound on lipid profile and lipid peroxidation in healthy volunteers. Clin Drug Invest 2003;23:193-203.
39. Noa M, Mendoza S, Más R, Mendoza N: Effect of D-003, a mixture of high molecular weight primary acids from sugar cane wax, on carbon tetrachloride-induced liver acute injury in rats. Drugs Exp Clin Res 2002;28:177-183.
40. Mendoza S, Noa M, Más R, Mendoza N: Effect of D-003 on paracetamol-induced hepatic damage in rats. Int J Tissue React 2003;25:91-98.
41. Sugiyama K, He P, Wada S, Saeki S: Teas and other beverages suppress D-galactosamine induced liver injury in rats. J Nutr 1999;129:1361-1367.
42. Wang B, Chang C, Egoshira Y, Ohta T, Savada H: Effects of oligosaccharides on galactosamiiie hepatitis in rats. Nippon Eujo Shoskuryo Gakkaishi 1995;48:181-187.
43. Gámez R, Más R, Noa M, et al.: Acute and subchronic oral toxicity of D-003 in rats. Toxicol Lett 2000;118:31-41.
44. Gámez R, Mas R, Noa M, et al.: A six months study of the oral toxicity of D-003 in Sprague Dawley rats. Drug R&D 2002;3:375-386.